Active Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) Homo sapiens (Human) Active protein

CD253; TNFSF10; APO2L; Apo2-L; TL2; TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point8.0
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) Packages (Simulation)
  • Active Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) Packages (Simulation)
  • APA139Hu02.jpg SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) is a member of the tumor necrosis factor (TNF) superfamily, mainly functioning to induce selective apoptosis in cancer cells while sparing normal cells. As a type II transmembrane protein, TRAIL binds to death receptors on the cell membrane, initiating the extrinsic apoptotic pathway. This selective cytotoxicity makes TRAIL a promising candidate for tumor immunotherapy. Upon receptor activation, TRAIL triggers a series of intracellular signaling events, including caspase activation and mitochondrial dysfunction, leading to cell death. Dysregulation of TRAIL signaling is associated with tumor progression and drug resistance. TRAIL recruits FADD through death domains to form the death-inducing signaling complex (DISC). Thus a functional ELISA assay was conducted to detect the interaction of recombinant human TRAIL and recombinant human FADD. Briefly, TRAIL was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to FADD-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-TRAIL pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human TRAIL and recombinant human FADD was shown in Figure 1, the EC50 for this effect is 0.00027 µg/mL.

Usage

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine ModelPubmed:25506835
  • Soluble TRAIL Concentration in Serum Is Elevated in People with HypercholesterolemiaPubMed: 26633016
  • Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in micepubmed:28507343
  • TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer PatientsPubmed: 31183506
  • Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNk/caspase-8/TRAIL activation in ratsPubmed: 32259601
  • Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signalingPubmed: 33199237
  • Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathwaysPubmed: 32942000
  • Tranilast abrogates cisplatin©\induced testicular and epididymal injuries: An insight into its modulatory impact on apoptosis/proliferation34047436

Recommend products